Population-Wide Evaluation of Disease Manifestation in Relation to Molecular Genotype in Steroid 21-Hydroxylase (CYP21) Deficiency: Good Correlation in a Well Defined Population1
Abstract
We report a population-wide analysis of all patients with 21-hydroxylase deficiency (21-OHD) found in Finland, a country with a genetically well defined population, in which the effects of other genetic and environmental factors on the phenotype can be expected to be low. In total, 120 patients were identified, and their clinical status was evaluated. Blood samples for CYP21 genotype determination could be obtained from 78 (65%) patients, and their phenotypes were compared with their genotypes. In general, the severity of gene defects correlated well with clinical expression. All patients carrying mutations with the most drastic effects on enzymatic activity had the salt-wasting form of 21-OHD. The I2 splice mutation, which in some reports has been connected with clinical variation, was constantly associated with severe mineralocorticoid deficiency. However, patients with I172N as the determining mutation expressed a wide spectrum of phenotypes; the variation could not be attributed to additional mutations. Although genetically affected males with the nonclassical form had not been clinically diagnosed, our study suggests that nonclassical 21-OHD is substantially more rare in Finland than elsewhere, as indicated by both clinical evaluation and mutational screening.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Deletions, the splice site mutation in intron 2 (c.293-13A/C>G) and p.Ile172Asn (I172N) are the most common mutations in most populations.
“Deletions, the splice site mutation in intron 2 (c.293-13A/C>G) and p.Ile172Asn (I172N) are the most common mutations in most populations (189,195-213).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [197]
Cites
Pang, S., Wallace, M. A., Hofman, L., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42164-1 · Cited by 392 · see citing works
Steroid 21-hydroxylase deficiency: genotype may not predict phenotype
Wilson, R. C. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.8.2322 · Cited by 324 · see citing works
Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency
Miller, W. L. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.2.241 · Cited by 167 · see citing works
Wedell, A., & Luthman, H. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.5.499 · Cited by 160 · cited 2× · see citing works
“In addition to these technical difficulties in mutation detection, discrepancies in genotype-phenotype correlation may result from de novo conversions, more than one partially inactivating mutation on a single allele, or unique singlefamily mutations, whose frequency does not seem to be negligible (7, 10, 11, 23, 26).”
BackgroundMethodMutations in steroid 21-hydroxylase (CYP21)
White, P. C., Tusie-Luna, M.-T., New, M. I., & Speiser, P. W. (1994) · Human Mutation · doi:10.1002/humu.1380030408 · Cited by 129 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556 · see citing works
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397 · see citing works
Genetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312 · see citing works
Finkielstain, G. P., Chen, W., Mehta, S. P., Fujimura, F. K., Hanna, R. M., Van Ryzin, C., McDonnell, N. B., & Merke, D. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0319 · Cited by 192 · see citing works
Stikkelbroeck, N. M. M. L., Hoefsloot, L. H., de Wijs, I. J., Otten, B. J., Hermus, A. R. M. M., & Sistermans, E. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021681 · Cited by 171 · see citing works
Nordenström, A., & Falhammar, H. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0712 · Cited by 158 · see citing works
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency
Krone, N., Dhir, V., Ivison, H. E., & Arlt, W. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02740.x · Cited by 131 · see citing works
Falhammar, H., & Nordenström, A. (2015) · Endocrine · doi:10.1007/s12020-015-0656-0 · Cited by 127 · see citing works
Bachega, T. A. S. S., Billerbeck, A. E. C., Madureira, G., Marcondes, J. A. M., Longui, C. A., Leite, M. V., Arnhold, I. J. P., & Mendonca, B. B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.12.5350 · Cited by 108 · see citing works
Hall, C. M., Jones, J. A., Meyer-Bahlburg, H. F. L., Dolezal, C., Coleman, M., Foster, P., Price, D. A., & Clayton, P. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030696 · Cited by 101 · see citing works
Marino, R., Ramirez, P., Galeano, J., Perez Garrido, N., Rocco, C., Ciaccio, M., Warman, D. M., Guercio, G., Chaler, E., Maceiras, M., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04123.x · Cited by 98 · see citing works
Jääskeläinen, J., & Voutilainen, R. (2000) · Acta Paediatrica · doi:10.1111/j.1651-2227.2000.tb01213.x · Cited by 89 · see citing works
Self-citationJunction Site Analysis of Chimeric CYP21A1P/CYP21A2 Genes in 21-Hydroxylase Deficiency
Chen, W., Xu, Z., Sullivan, A., Finkielstain, G. P., Van Ryzin, C., Merke, D. P., & McDonnell, N. B. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.174037 · Cited by 86 · see citing works
Nandagopal, R., Sinaii, N., Avila, N. A., Van Ryzin, C., Chen, W., Finkielstain, G. P., Mehta, S. P., McDonnell, N. B., & Merke, D. P. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0019 · Cited by 81 · see citing works
Biochemical and genetic diagnosis of 21-hydroxylase deficiency
Falhammar, H., Wedell, A., & Nordenström, A. (2015) · Endocrine · doi:10.1007/s12020-015-0731-6 · Cited by 80 · see citing works
Pituitary gonadal axis and child rate in males with classical 21-hydroxylase deficiency
Jääskeläinen, J., Kiekara, O., Hippeläinen, M., & Voutilainen, R. (2000) · Journal of Endocrinological Investigation · doi:10.1007/bf03343671 · Cited by 71 · see citing works
Self-citationRiedl, S., Röhl, F.-W., Bonfig, W., Brämswig, J., Richter-Unruh, A., Fricke-Otto, S., Bettendorf, M., Riepe, F., Kriegshäuser, G., Schönau, E., et al. (2019) · Endocrine Connections · doi:10.1530/ec-18-0281 · Cited by 69 · see citing works
Prenatal treatment of congenital adrenal hyperplasia
Lajic, S., Nordenstrom, A., Ritzen, E., & Wedell, A. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.151u063 · Cited by 67 · see citing works
Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency
Charmandari, E., Eisenhofer, G., Mehlinger, S. L., Carlson, A., Wesley, R., Keil, M. F., Chrousos, G. P., New, M. I., & Merke, D. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8664 · Cited by 70 · see citing works
The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0304 · Cited by 52 · see citing works
Araujo, R. S., Billerbeck, A. E. C., Madureira, G., Mendonca, B. B., & Bachega, T. A. S. S. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02184.x · Cited by 42 · see citing works
Xu, C., Jia, W., Cheng, X., Ying, H., Chen, J., Xu, J., Guan, Q., Zhou, X., Zheng, D., Li, G., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.671 · Cited by 29 · see citing works
Kocova, M., Anastasovska, V., & Falhammar, H. (2020) · Endocrine · doi:10.1007/s12020-020-02323-3 · Cited by 24 · see citing works
Characteristics of In2G Variant in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Kocova, M., Concolino, P., & Falhammar, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.788812 · Cited by 15 · see citing works
Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency
Speiser, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8737 · Cited by 3 · see citing works
- Authors
- Jääskeläinen, J., Levo, A., Voutilainen, R., & Partanen, J.
- Affiliations
- Kuopio University Hospital (FI)
- Finnish Red Cross (FI)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-10
- Volume
- 82
- Issue
- 10
- Pages
- 3293-3297
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2094567176
- Cited by
- 149
- References
- 5
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 5 · 2012: 7
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Maud Kuistilan Muistosäätiö
- Lastentautien Tutkimussäätiö
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- 21-hydroxylase deficiency, CYP21, genotype-phenotype correlation, salt-wasting phenotype, mineralocorticoid deficiency, congenital adrenal hyperplasia, mutation detection
- MeSH terms
- Adrenal Hyperplasia, Congenital, Child, Preschool, DNA, Recombinant, Female, Genotype, Humans, Male, Mineralocorticoids, Mutation, Phenotype, Steroid 21-Hydroxylase, Genetic Variation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
